Abstract: A supplement formulation including a combination of vitamins, minerals, amino acids, and stimulants, and a delivery method and device for said supplement formulation. Caffeine is present in the supplement formulation in an amount of about 40-60 mg/ml, of which about 15-30 mg/ml is caffeine from coffee beans and about 15-30 mg/ml is caffeine from green tea extract. About 5-20 mg/ml caffeine from guarana seed extract may also be present. Such a delivery device provides the supplement to a mouth/throat area of a user where it is readily absorbed in the mouth/throat area of the user or ingested by the user.

Abstract: The present invention relates to combination of one or more SGLT2 inhibitors or pharmaceutically acceptable forms and/or salts thereof and one or more dopamine receptor agonists or pharmaceutically acceptable forms and/or salts thereof, preferably in the treatment and/or prevention of a metabolic disorder of an equine animal, wherein more preferably the metabolic disorder is one or more disorders selected from Equine Metabolic Syndrome (EMS), Equine Pituitary Pars Intermedia Dysfunction (PPID), also known as equine Cushing's syndrome, laminitis, vascular dysfunction, hypertension, hepatic lipidosis, hyperadreeocorticism, glucose intolerance, insulin resistance, hyperinsulinaemia, hirsutism, hyperhidrosis. polyuria, polydipsia, chronic infections, abnormal fat distribution, muscle wasting, abnormal weight loss and/or loss of appetite.

Abstract: The present disclosure provides compositions containing ketamine and methods of using those compositions for the treatment of post-traumatic stress disorder. Also provided herein is a pharmaceutical composition that comprises esketamine and a pharmaceutically acceptable carrier, excipient or diluent, for use in treatment of PTSD. In some aspects, the pharmaceutical composition is for intranasal or intravenous administration. In some aspects, the pharmaceutical composition is for use in a method of treating PTSD in a subject. In some aspects, the pharmaceutical composition is for use in a method of treating major depressive disorder in a subject that is co-morbid with the PTSD.

Abstract: The present disclosure is a composition, a method of making the composition and method of using such composition preferably in the form of a dietary supplement that, when administered, is capable of treating insomnia and other sleep-related disorders. The unique combination of the composition is preferably administered orally. The composition is preferably comprised of at least vitamin B6, chamomile extract, passionflower extract, lemon balm extract, L-Theanine, GABA, 5-Hydroxytryptophan, and melatonin, in pre-determined amounts. The composition can further comprise a palliative agent, and can be provided in the form of a capsule, powder, liquid or tablet.

Abstract: The present invention provides an antiseptic composition comprising a germinant and an antimicrobial agent, wherein the germinant increases a pathogen's susceptibility to attack from the antimicrobial agent and wherein the antimicrobial agent does not inhibit the germinant. The present invention also provides an antiseptic wipe, handwash or paint comprising such antiseptic composition and a method of sterilizing a surface using such a composition.

Abstract: The invention provides immunochromatographic test strips and methods for detecting and quantifying S-Adenosylmethionine (SAM), S-Adenosylhomocysteine (SAH) and Homocysteine (HCy) in a sample, comprising: (a) making fluorophore conjugated antibodies; (b) immobilizing SAM, SAH and HCy on a solid support; (c) providing a sample, combining said sample with a conjugate selected from the group consisting of lanthanide chelate conjugates and quantum dot conjugates (QD) with anti-SAM, anti-SAH or anti-HCy, wherein said combining is performed under conditions that allow formation of a competitive complex comprising said conjugate, said SAM, SAH or HCy on the solid support and SAM, SAH or HCy in a sample when present; and (d) detecting the presence of the complex, if present, by monitoring a spectral emission mediated by the fluorescent conjugates in the complex, wherein the emission indicates the presence and quantity of SAM, SAH or HCy in the sample.

Abstract: The present invention refers to novel compositions and to methods of using the compositions to treat and/or prevent obesity, obesity-related diseases or disorders (e.g., hyperglycemia, hyperinsulinemia, elevated hemoglobin A1c (HbA1c), diabetes, or cardiovascular disease), and overweight. This invention also generally relates to compositions and to methods of using the compositions to increase basal metabolic rate.

Abstract: The present invention provides a composition for topical treatment of skin and mucosal membrane lesions comprising a synergistic combination of copper compound and hypericum perforatum extract.

Abstract: The present invention is directed to nutritional and nutraceutical compositions which comprise novel mixtures of two or more indole-based dietary supplements such as L-tryptophan and melatonin, together with selected minerals and vitamins that stimulate tryptophan metabolism in the direction of serotonin and melatonin, and to their use in a preferred embodiment of the invention in a readily ingested beverage form, optionally combined with a range of other natural ingredients designed to improve the health and state of mind of human subjects. Alternative dosage forms, such as tablets for oral dosing, and dosage forms for buccal and sublingual administration, including thin films, are also incorporated in the present invention. Health improvements include the treatment of disorders of circadian rhythm, such as shift work disorder and jet lag, the induction of relaxation and a restful frame of mind, as well as providing restorative sleep function.

Abstract: A water-soluble anti-inflammatory cream is disclosed. The cream is a composition of between about 7.5% and about 30% by weight of a healing oil; between about 1% and about 6% by weight of an herbal extract; between about 0% and about 3.5% by weight of microencapsulated amino acids; and at least 39.4% by weight water.

Abstract: Disclosed is the use of hypericum (Hypericum perforatum L.) tip extracts containing hypericin, of hypericin, to prepare medicinal products and/or food supplements for the treatment of neuropathic pain.

Abstract: The invention relates to an active ingredient and/or to a composition having beneficial effect on neurological and cognitive functions.

Abstract: An object of this invention is to provide a sleep improvement composition, which contains theanine and other components and can be used safely by anybody on a daily basis without side effects. This object is attained by a sleep improvement composition comprising: (a) theanine; and (b) at least one component selected from the group consisting of chamomile, lavender, Saint John's wort, kawakawa, valerian, passion flower, tryptophan, ?-aminobutyric acid, serotonin, melatonin, and cedrol.

Abstract: A method of detecting the presence or absence of a disease in a patient wherein said disease is accompanied by deficient levels of S-adenosylmethionine comprising: identifying a patient that is suspected of having said disease or is at risk of having said disease; obtaining a biological sample from said patient; determining the level of S-adenosylmethionine in said biological sample using an antibody derived from a hapten analog of S-adenosylmethionine; and correlating the level of S-adenosylmethionine in said biological sample with the presence or absence of said disease. The invention also provides methods for measuring SAH which is used to determine the methylation index (ratio of SAM/SAH) in biological fluids which is indicative of the health status of an individual.

Abstract: This invention relates to a composition, and methods of administration and treatment comprising a homeopathic preparation of an effective amount of Spermine and/or Spermidine that improves hormone imbalances in males and females. The purpose of the invention is to provide a homeopathic treatment comprising Spermine and/or Spermidine that demonstrates improvement in energy, sleep, sexual function, relief of prostrate symptoms, lighter and shorter hot flush symptoms, stamina, weight loss, and the overall mood and stress of a patient.

Abstract: An herbal ointment. The herbal ointment may include about 40-45 weight percent of herb-infused oil, water or alcohol, or any desired combination thereof, about 30 weight percent purified water, about 10 weight percent emulsifier wax, about 5-10 weight percent menthol, about 3 weight percent dimethyl isosorbide, about 2 weight percent glycerin, about 2 weight percent hydrogenated methyl abietate, about 0.5 weight percent lonicera caprifolium and lonicera japanica extract, about 0.5 weight percent tocopherol, about 0.35 weight percent vanillyl butyl ether, about 0.35 weight percent xanthan gum, about 0.3 weight percent citric acid 50% aqueous solution, and about 0.25 weight percent menthyl lactate, the herb-infused oil, water or alcohol including a 1:5 dilution of herbal extracts in a solvent, wherein the herbal extracts are of German Chamomile (Matricaria recutita), Valerian (Valeriana officinalis), Ginger (Zingiber officinale Roscoe), Peppermint (Mentha.times.

Abstract: A water-soluble anti-inflammatory cream is disclosed. The cream is a composition of between about 7.5% and about 30% by weight of a healing oil; between about 1% and about 6% by weight of an herbal extract; between about 0% and about 3.5% by weight of microencapsulated amino acids; and at least 39.4% by weight water.

Abstract: The invention relates to the use of ironwort extracts that can be obtained by means of extracting using water or water-alcohol solvents or mixtures thereof, for producing a formulation, and for treating or preventing neurodegenerative diseases.

Abstract: The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a therapeutically effective amount of esketamine as mono-therapy or as combination therapy with at least on antidepressant.

Abstract: The invention relates to a pharmaceutical composition containing active vegetable substances and a mixture made of a polymeric water-soluble and a polymeric water-insoluble matrix forming agent. Said pharmaceutical composition is suitable for the oral administration of active vegetable substances with delayed release.

Abstract: Disclosed are a novel combination of specific therapeutics selected from S-adenosyl methionine or a salt thereof, folic acid or a metabolite or salt thereof, and one or more omega-3 fatty acids or salts thereof, useful for a variety of conditions, as discussed herein. Methods of treatment include the treatment of neuropsychiatric conditions, such as depression.

Abstract: A topical composition is prepared using macerated leaves of St. Andrew's Cross (hypericum hypericoides). An aqueous extract of the leaves is mixed with ethanol to form a spray or to saturate a wet wipe and administer to a mammal skin for treatment a variety of skin conditions, including eczema, psoriasis, rosacea, cellulitis, contact dermatitis, seborrhoeic dermatitis, nummular dermatitis, dandruff, stasis dermatitis, perioral dermatitis, dermatitis herpetiformis, ecthyma, impetigo, shingles, urticaria, tinea pedis, tinea manuum, tinea cruris, sunburn, insect bites and stings, jellyfish stings, granuloma annulare, bullous pemphigoid, lichen planus, bed sore, inflammations caused by waterborne vectors, diaper rash, heat rash, pityriasis rosea, jungle rot, scleroderma, skin rashes and photo-aging.

Abstract: The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a therapeutically effective amount of esketamine as mono-therapy or as combination therapy with at least on antidepressant.

Abstract: Disclosed are a novel combination of specific therapeutics selected from S-adenosyl methionine or a salt thereof, folic acid or a metabolite or salt thereof, and one or more omega-3 fatty acids or salts thereof, useful for a variety of conditions, as discussed herein. Methods of treatment include the treatment of neuropsychiatric conditions, such as depression.

Abstract: This invention describes a comprehensive nutraceutical designed to antagonize major mitigating factors to the degenerative process associated with Parkinson's disease. The formulation is comprised of a primary base of pyruvate, succinate, ?-Ketoglutarate and/or oxaloacetate, niacin/NADH, fruit extracts, anthocyanins, further combined with specific macro/micronutrients, trace elements, amino acids, flavonoids and concentrated plant sources. The nutraceutical contains all natural substances that should mitigate many of the neurodegenerative processes known to be associated with PD. Mechanisms addressed are to prevent the loss of ATP/by 1-methyl-4-phenylpyridinium rotenone, scavenge hydrogen peroxide/O2.

Abstract: The invention relates to the use of bedstraw extracts that can be obtained by means of extracting using water or water-alcohol solvents or mixtures thereof, for producing a formulation, and for treating or preventing neurodegenerative diseases.

Abstract: An object of the present invention is to provide prevent or improve decreases in the barrier function and moisture retention function of the skin, and that object is achieved by applying an external preparation for skin that comprises a matrix metalloproteinase inhibitor and a heparanase inhibitor.

Abstract: Compositions comprising from about 40 weight parts to about 1000 weight parts of a botanical nitrate source; from about 20 weight parts to about 500 weight parts of a botanical source of nitrite reduction activity; and from about 4 weight parts to about 100 weight parts of a nitrite salt. Methods of reducing triglycerides or reducing C-reactive protein levels are also provided.

Abstract: A method of testing a substance potentially active in the field of lipolysis comprising: preparing a substrate containing at least one triacylglycerol; placing this substrate in contact with a substance potentially active in the field of lipolysis, and with a lipoprotein lipase, in the presence of a cofactor of lipoprotein lipase, for a period of time sufficient to release at least in part one fatty acid of the triacylglycerol; and determining the capacity of inhibition of the release of the fatty acid resulting from the activity of the lipoprotein lipase, under the action of said potentially active substance, and evaluating the result of the inhibition which is either compared to the result obtained in the absence of the potentially active substance tested or compared with the result obtained in the presence of a known inhibitor acting as reference. Cosmetic and pharmaceutical uses are described.

Abstract: Disclosed is a water based topical pain relieving composition that is substantially odorless and does not leave a greasy or oily residue behind. The water based topical pain relieving composition may be particularly useful in treating areas near the eyes or mucous membranes. In some embodiments the topical pain relieving composition may comprise a water based emulsion comprising an effective amount of an analgesic composition comprising trolamine salicylate and an inflammation reducing composition comprising effective amounts of Anthemis Nobilis (roman chamomile) extract, Arnica Montana flower extract, Calendula Officinalis (marygold) extract, Centaurea Cyanus (blue bottle) extract, inflammation reducing oil, Hypericum Perforatum (St. John's Wort) extract, Matricaria Chamomilla (Wild Chamomile) extract, methylsulfonylmethane (MSM), Salix Alba (willow) bark extract, sorbitol, Tilia Sylvestris (limetree) extract, and aloe vera concentrate.

Abstract: The present invention relates to nutritional supplement compositions comprising krill meal and lipid insoluble ingredients. The compositions can be used to provide supplementary nutrition to humans or animals. The present invention relates also formulations, such as tablets, which are easy to administer to animals. It is also shown that krill meal added to animal food at low levels will improve the palatability of the product.

Abstract: The present invention relates to compositions including a homeopathic aqueous substance active (HASA) and at least one hydrophilic gelling agent, the HASA comprises a homeopathic compound at a potency of 30 C or higher and an uninhibited aqueous composition. The present invention also relates to methods of preparing a hydrophilic HASA-gel matrix. The method includes combining a homeopathic compound and an uninhibited aqueous composition to produce a HASA; combining the HASA with at least one hydrophilic gelling agent; and thereafter, forming the hydrophilic HASA-gel matrix by use of at least one of a thickening agent, a crosslinking agent, or a polymerization agent.

Abstract: Disclosed herein is a method of using megestrol acetate. In one embodiment, the method comprises informing a user that megestrol acetate is metabolized by a cytochrome p450 isozyme. In another embodiment, the method comprises obtaining megestrol acetate from a container associated with published material providing information is metabolized by a cytochrome p450 siozyme. Also disclosed are articles of manufacture comprising a container containing a dosage form of megestrol acetate, wherein the container is associated with published material informing that megestrol acetate is metabolized by a cytochrome p450 siozyme, a method of treatment, and a method of manufacturing a megestrol acetate product.

Abstract: The invention encompasses novel compositions containing a methylation modifying compound isolated from botanical raw materials, including a fruit of the genus Coffea, and microbial raw materials, methods of making such compositions, and methods of treating or preventing human disease using such compositions. The methylation modifying compound in botanical extracts of the present invention can dramatically increase the level of methylation of PP2A, thus increasing cognitive function, particularly in persons suffering from or prone to developing Alzheimer's disease.

Abstract: A method for making a Hypericum perforatum extract in Neem oil, provides of: combining an amount of Hypericum flowers and/or capsules with a quantity of Neem oil; introducing into a reactor the mixture made of the amounts of Hypericum flowers and/or capsules and of Neem oil; maintaining the mixture vacuum, under agitation for a predefined time and temperature. A composition includes Neem oil and Hypericum flowers and/or capsules. Such composition includes moreover a solvent or a mixture of solvents.

Abstract: The present invention provides a method of treating neuropathic pain by administering a topical homeopathic composition to a mammalian subject. The homeopathic formulation contains homeopathic active ingredients comprising Hypericum perforatum in a base of essential oils which facilitate delivery of the homeopathic ingredient through the skin.

Abstract: Cannabinoid compositions and methods of administering said cannabinoid compositions are disclosed. The cannabinoid compositions disclosed herein include compounds which have been strategically selected to eliminate, or least mitigate, one of the negative side effects associated with consuming cannabinoids. A daytime formula includes compounds aimed at nullifying the negative side effects that cannabinoid consumption has on a patient's daily operations and activities. A nighttime formula includes compounds aimed at nullifying the negative side effects that cannabinoid consumption has a patient's sleep.

Abstract: Contemplated compositions and methods utilize a combination of a polyphenol and a non-polyphenol cyclooxygenase-2 inhibitor. Preferably, the compositions are pharmaceutical and/or nutraceutical compositions and formulated in a dosage form and amount such that the polyphenol and the non-polyphenol cyclooxygenase-2 inhibitor are effective to reduce tumor incidence and/or multiplicity. In preferred aspects, the polyphenol is epigallocatechin gallate, epigallocatechin, epicatechin gallate, epicatechin, and/or a mixture of polyphenols isolated from a plant (e.g., polyphenon E), and the cyclooxygenase-2 inhibitor is rofecoxib, celecoxib, and/or valdecoxib.

Abstract: The present invention includes a cranberry seed oil, a cranberry flour and a method for making cranberry seed oil and flour. The cranberry seed oil comprises beta sitosterol and phosphatidylcholine.

Abstract: Provided, among other things, is a slowly dissolvable film comprising: herbal bioactive agent(s); and polymer(s), dissolvable in the aggregate, wherein the film becomes adhesive as it is placed against a mucosal surface and begins to absorb moisture therefrom.

Abstract: The present invention provides therapeutic compositions comprising extracts of the plant species Echinacea purpurea and Sambucus nigra and the extract(s) of at least one further plant selected from the group consisting of Hypericum perforatum, Commiphora molmol and Centella asiatica. The compositions of the invention are of particular utility in the management of inflammatory mucosal diseases of both viral and non-viral origin.

Abstract: The present invention refers to pharmaceutical, dietary and/or nutraceutical orosoluble and/or effervescent compositions for oral use containing at least a salt of S-adenosyl methionine (SAMe), combined with physiologically acceptable excipients and optionally additional active ingredients. In particular the invention refers to compositions with high palatability formulated in tablet, capsule or granules. The present invention also refers to the use of at least a salt of SAMe combined with physiologically acceptable excipients and optionally further active ingredients for treating, human or veterinarian, neuropsychiatric, osteoarticular or hepatic diseases.

Abstract: Disclosed herein is a method of using megestrol acetate. In one embodiment, the method comprises informing a user that megestrol acetate is metabolized by a cytochrome p450 isozyme. In another embodiment, the method comprises obtaining megestrol acetate from a container associated with published material providing information is metabolized by a cytochrome p450 isozyme. Also disclosed are articles of manufacture comprising a container containing a dosage form of megestrol acetate, wherein the container is associated with published material informing that megestrol acetate is metabolized by a cytochrome p450 isozyme, a method of treatment, and a method of manufacturing a megestrol acetate product.

Abstract: The method of human prophylaxis comprising a number of steps is claim. First, the client is prepared for a steam bath, by applying a herbal paste on the skin, over at least one area of the client's body. The herbal paste is allowed to be absorbed into the client's body for an amount of time of at least five minutes and is followed with a massage the client's body. The client is then placed into a cedar steam barrel, connected to the steam generator, where the client's body is exposed to the steam. Following the stream procedure, the herbal paste is reapplied, the client's body is massaged, and the client to rests and drinks at least one cup of tea.

Abstract: Method of selecting and preparing medical devices comprising extracts of plants and natural substances devoid of pharmacologically, immunologically or metabolically active fractions and characterised by a content of substances able to exert beneficial effects on the body, mediated by mechanical or physical effects, which said process comprises: a) removal by conventional processes of any pharmacologically, immunologically or metabolically active fractions from extracts of plants or natural substances; b) biological testing to establish that the extract or substance obtained in a) is devoid of pharmacological, metabolic and immunological effects; c) formulation of the extracts or substances that pass the test conducted at stage b) into suitable medical devices.

Abstract: An herbal ointment. The herbal ointment may include about 45 weight percent of herb-infused oil, water or alcohol, or any desired combination thereof, about 30 weight percent purified water, about 10 weight percent emulsifier wax, about 5 weight percent menthol, about 3 weight percent dimethyl isosorbide, about 2 weight percent glycerin, about 2 weight percent hydrogenated methyl abietate, about 0.5 weight percent lonicera caprifolium and lonicera japanica extract, about 0.5 weight percent tocopherol, about 0.35 weight percent vanillyl butyl ether, about 0.35 weight percent xanthan gum, about 0.3 weight percent citric acid 50% aqueous solution, and about 0.

Abstract: Disclosed are a novel combination of specific therapeutics selected from S-adenosyl methionine or a salt thereof, folic acid or a metabolite or salt thereof, and one or more omega-3 fatty acids or salts thereof, useful for a variety of conditions, as discussed herein. Methods of treatment include the treatment of neuropsychiatric conditions, such as depression.

Abstract: Cosmetic or dermopharmaceutical compositions containing Pseudoalteromonas ferment extract for the treatment and/or care of the skin, scalp and/or nails, preferably to improve the barrier function of the skin, scalp and/or nails, and specifically for the treatment and/or care of those conditions, disorders and/or pathologies of the skin, scalp and/or nails associated with an alteration in the keratinization process.

Abstract: The present invention provides a proprietary compositions and systems to modulate genetic and metabolomic contributing factors affecting disease diagnosis, stratification, and prognosis, as well as the metabolism, efficacy and/or toxicity associated with specific vitamins, minerals, herbal supplements, homeopathic ingredients, and other ingredients for the purposes of customizing a subject's nutritional supplement formulation to optimize specific health outcomes. Specific to this invention the utilization of certain known polymorphic genes associated with Substance Use Disorder (SUD) are analyzed to target certain genetic anomalies that lead to a high risk and predisposition to SUD. The genotypic patterns are then utilized to provide certain nutritional customized solutions especially related to the attenuation of aberrant abuse of physician prescribed narcotic pain medication across all pain conditions.

Abstract: Provided are methods of topical application of an aqueous homeopathic composition for treating various ailments and injuries, including deep tissue wounds and surgical wounds. The aqueous homeopathic composition is formulated in a high potency of at least 400 C, maintained in an aqueous medium and topically applied to a bodily surface for an extended period of time to render therapeutic treatment.